Metabolic syndrome, endocrine disruptors and prostate cancer associations: Biochemical and pathophysiological evidences

Oncotarget

Volumn 8, Issue 18, 2017, Pages 30606-30616

  Quagliariello, Vincenzo ^a,b,h   Rossetti, Sabrina ^a,b   Cavaliere, Carla ^a,c   Di Palo, Rossella ^a,b   Lamantia, Elvira ^a,b   Castaldo, Luigi ^a,b   Nocerino, Flavia ^b   Ametrano, Gianluca ^a,b   Cappuccio, Francesca ^a,b   Malzone, Gabriella ^a,b   Montanari, Micaela ^a,d   Vanacore, Daniela ^a   Romano, Francesco Jacopo ^a   Piscitelli, Raffaele ^a,b   Iovane, Gelsomina ^b   Pepe, Maria Filomena ^a,b   Berretta, Massimiliano ^e,h   D'Aniello, Carmine ^a,f   Perdonà, Sisto ^b   Muto, Paolo ^b   Botti, Gerardo ^b   Ciliberto, Gennaro ^b   Veneziani, Bianca Maria ^d   De Falco, Francesco ^b   Maiolino, Piera ^b   Caraglia, Michele ^g   Montella, Maurizio ^b   Iaffaioli, Rosario Vincenzo ^b,h   Facchini, Gaetano ^a,b,h   more..

^a Linea pro 14 per l'impl della prevenzione e diagnosi precoce del tumore alla prostata e testicolo ^*  (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c S G MOSCATI HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f MONALDI HOSPITAL   (Italy)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

^h Association for Multidisciplinary Studies in Oncology and Mediterranean Diet   (Italy)

Author keywords

Cancer; Endocrine disruptors; Metabolic syndrome; Nutrition; Prostate

Indexed keywords

4 HYDROXYNONENAL; 4,4' ISOPROPYLIDENEDIPHENOL; ADIPOCYTOKINE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CYTOKINE; ENDOCRINE DISRUPTOR; ENDOSULPHAN; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LINDANE; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE INHIBITORY CYTOKINE TYPE 1; MALONALDEHYDE; NONYLPHENOL; PHTHALIC ACID; PROPOXUR; PROSTATE SPECIFIC ANTIGEN; SELENIUM; SOMATOMEDIN C; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ABDOMINAL OBESITY; ANDROGEN DEPRIVATION THERAPY; APC GENE; BLOOD BRAIN BARRIER; BODY MASS; CANCER CELL; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL SURVIVAL; DIETARY INTAKE; DISEASE ASSOCIATION; DNA METHYLATION; DNA MODIFICATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GLEASON SCORE; GSTP1 GENE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; INTERVENTION STUDY; MACROPHAGE; METABOLIC SYNDROME X; METABOLISM; MORBIDITY; MORTALITY; NUTRITION; OBESITY; ONCOGENE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; PROSTATE CANCER; PROSTATECTOMY; RASSF1A GENE; REVIEW; WAIST HIP RATIO;

EID: 85018945089     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16725     Document Type: Review

References (90)

1. Capocaccia R, Foschi R, Zucchetto A, Valdagni R, Nicolai N, Maffezzini M, Gatta G. Estimates of prostate cancer burden in Italy. Cancer Epidemiol. 2016 ;40:166-72
2. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006; 11:1388-413
3. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev. 2001;23:3-13
4. Kaur J. A Comprehensive Review on Metabolic Syndrome. Cardiol Res Pract. 2014; 2014:943162
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA.2002;287:356-359
6. O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obesity Reviews. 2015; 16;1-12
7. Armstrong AW. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013; 27;68:654-62
8. Katzmarzyk PT, Church T.S, Janssen I, Ross R, Blair SN. Metabolic Syndrome, Obesity, and Mortality. Diabetes Care February. 2005; 28:.2391-397
9. Guizea L, Panniera B, Thomasa F, Beana K, Jégoa K, Benetosa A. Recent advances in metabolic syndrome and cardiovascular disease. Archives of Cardiovascular Diseases. 2008; 101:577-583
10. Wannamethee S G, The metabolic syndrome and cardiovascular risk in the British Regional Heart Study. International Journal of Obesity.2008; 32:25-29
11. Zhuo Q, Yang W. Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol. 2012; 8:729-37
12. Watts AS. Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adults. J Alzheimers Dis. 2013;35:253-65
13. Chen Y, Wen YY, Li ZR, Luo DL, Zhang XH. The molecular mechanisms between metabolic syndrome and breast cancer. Biochem Biophys Res Commun. 2016; 18;471:391-5
14. Karzai FH, Madan RA, Dahut WL. Metabolic syndrome in prostate cancer: impact on risk and outcomes. Future Oncol. 2016; 12:1947-55
15. Rosatoa V, Tavania A, Bosettia C, Pelucchia A, Talaminib R, Poleselb J, Serrainob D, Negria E, La Vecchia C. Metabolic syndrome and pancreatic cancer risk: a casecontrol study in Italy and meta-analysis. Metabolism 2011; 60: 1372-1378
16. García-Jiménez C, Gutiérrez-Salmerón M, Chocarro-Calvo A, García-Martinez JM, Castaño A, De la Vieja A. From obesity to diabetes and cancer: epidemiological links and role of therapies. Br J Cancer. 2016; 29;114:716-22
17. Mello T, Materozzi M, Galli A. PPARs and Mitochondrial Metabolism: From NAFLD to HCC. PPAR Res. 2016;2016:7403230
18. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012; 35:2402-11
19. Kiwata J L, Dorff TB, Schroeder ET, Gross ME, Dieli-Conwright CM. A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. Prostate Cancer and Prostatic Diseases. 2016; 19: 323-332
20. Conteduca V, Caffo O, Derosa L, Veccia A, Petracci E, Chiuri V, Santoni M, Santini D, Fratino L, Maines F, Testoni S, De Giorgi U. Metabolic syndrome in castrationresistant prostate cancer patients treated with abiraterone Prostate. 2015 ;75:1329-38
21. De Nunzio C, Simone G, Brassetti A, Mastroianni R, Collura D, Muto G, Gallucci M, Tubaro A. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study. BMC Cancer. 2016; 16: 407
22. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007;109:875-81
23. Xiang Y, Xiong H, Cui Z, Jiang S, Xia Q, Zhao Y, Li G, Jin X. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. Journal of Experimental & Clinical Cancer Research. 2013; 32:9
24. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and metaanalysis. Int J Cancer. 2009; 124:2416-29
25. Hsing AW, Deng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Benichou J, Xie T, Gao YT. Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 2000;9:1335-41
26. Rowlands M, Holly J, Gunnell D, Donovan J, Lane A, Hamdy F, Neal D, Oliver S, Smith D, Martin RM. Circulating insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) in PSA-detected prostate cancer: the large case control study ProtecT. Cancer Res. 2012; 72:503-515
27. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, Cohen P, Hwang D, Peterson B, Fields T, Pizzo SV, Isaacs WB. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate. 2008; 1;68:11-9
28. Ong SC, McNeil KA, Delaine C, Booker GW, Wallace JC, Forbes BE. Understanding the mechanism of insulin and insulin-like growth factor (IGF) receptor activation by IGFII. PLoS ONE. 2011 ;6:e27488
29. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. JUrol. 2004;172:S6-11
30. Xu J, Lowey J, Wiklund F. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk.Cancer Epidemiol Biomarkers Prev. 2005; 14:2563-8
31. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006; 83:461S-5S
32. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006. 94: 1221-1225
33. Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 2014;113:986-92
34. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 2001;12:33-40
35. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology. 1995; 45:542-9
36. Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate. 2004;60:178-86
37. Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res. 2006;15;12:5578-86
38. Lessard L, Begin L R, Gleave M E, Mes-Masson A M, Saad F. Nuclear localisation of nuclear factorkappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 2005;93: 1019-23
39. Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, Jung K, Diamandis EP. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer. 2003 ;88:1101-4
40. Waugh DJ, Wilson C. The Interleukin-8 Pathway in Cancer. Clin Cancer Res. 2008;14:6735-41
41. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000;6:2104-19
42. Yubero-Serrano E, Delgado-Lista J, Peña-Orihuela P, Perez-Martinez P, Fuentes F, Marin C, Tunez I, Tinahones FJ, Perez-Jimenez F, Roche HM, Lopez-Miranda L. Oxidative stress is associated with the number of components of metabolic syndrome: LIPGENE study. Experimental & Molecular Medicine. 2013; 45, e28
43. Moreto F, De Oliveira EP, Manda R, Burini RC. The Higher Plasma Malondialdehyde Concentrations Are Determined by Metabolic Syndrome-Related Glucolipotoxicit. Oxid Med Cell Longev. 2014; 2014: 505368
44. Shiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. The Prostate. 2005;64:92-100
45. Yang S, Pinney SM, Mallick P, Ho SM, Bracken B, Wu T. Impact of Oxidative Stress Biomarkers and Carboxymethyllysine (an Advanced Glycation End Product) on Prostate Cancer: A Prospective Study. Clin Genitourin Cancer. 2015;13:e347-51
46. Dillioglugil MO, Mekk H, Muezzinoglu B, Ozkan TA, Demir CG, Dillioglugil O. Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer. Int Urol Nephrol. 2012; 44:1691-6
47. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, Ma J. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010;56:34-43
48. Stattin P, Söderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH, Bergh A, Olsson T. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab. 2001;86:1341-5
49. Shapiro A, Mu W, Roncal C, Cheng KY, Johnson RJ, Scarpace PJ. Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. Am J Physiol Regul Integr Comp Physiol. 2008;295:R1370-5
50. Liao Q, Long C, Deng Z, Bi X, Hu J. The role of circulating adiponectin in prostate cancer: a meta-analysis. Int J Biol Markers. 2015;30:e22-31
51. Frye CA, Bo E, Calamandrei G, Calzà L, Dessì-Fulgheri F, Fernández M, Fusani L, Kah O, Kajta M, Le Page Y, Patisaul HB, Venerosi A, Wojtowicz AK, Panzica GC. Endocrine disrupters: a review of some sources, effects, and mechanisms of actions on behaviour and neuroendocrine systems. J Neuroendocrinol. 2012 ;24:144-59
52. Casals-Casas C, Desvergne B. Endocrine disruptors: from endocrine to metabolic disruption. Annu Rev Physiol. 2011;73:135-62
53. Erickson B. Bisphenol A under Scrutiny. Chemical & Engineering News. 2008, 86 :36-39
54. Derouiche S, Warnier M, Mariot P, Gosset P, Mauroy B, Bonnal J, Slomianny C, Delcourt P, Prevarskaya N, Roudbaraki M. Bisphenol A stimulates human prostate cancer cell migration via remodelling of calcium signaling. Springerplus. 2013; 2:54
55. Tarapore P, Ying J, Ouyang B, Burke B, Bracken B, H. Exposure to bisphenol A correlates with early-onset prostate cancer and promotes centrosome amplification and anchorage-independent growth in vitro. PLoS One. 2014;9:e90332
56. Harris, C. A., Henttu, P., Parker, M. G., and Sumpter, J. P. The estrogenic activity of phthalate esters in vitro. Environ. Health Perspect. 1997; 105: 802-811
57. Richard W. Stahlhut,1 Edwin van Wijngaarden, Timothy D. Dye, Stephen Cook, Shanna H. Swan Concentrations of Urinary Phthalate Metabolites Are Associated with Increased Waist Circumference and Insulin Resistance in Adult U.S. Males. Environ Health Perspect. 2007; 115: 876-882
58. Lee HR, Hwang KA, Choi KC. The estrogen receptor signaling pathway activated by phthalates is linked with transforming growth factor-in the progression of LNCaP prostate cancer models. Int J Oncol. 2014; 45:595-602
59. Saiyed H, Dewan A, Bhatnagar V, Shenoy U, Shenoy R, Rajmohan H, Rekha Kashyap P, Kulkarni P, Rajan B, Lakka. Effect of Endosulfan on Male Reproductive Development. Environmental Health Perspectives. 2003; 111: 1958-1962
60. Damgaard IN, Skakkebaek NE, Toppari J, Virtanen HE, Shen H, Schramm KW, Petersen JH, Jensen TK, Main KM. Persistent pesticides in human breast milk and cryptorchidism.; Nordic Cryptorchidism Study Group Environ Health Perspect. 2006; 114:1133-8
61. Bajpayee M, Pandey AK, Zaidi S, Musarrat J, Parmar D, Mathr N, Seth PK, Dhawan A. DNA damage and mutagenicity induced by endosulfan and its metabolites. Environ Mol Mutagen. 2006; 47: 682-692
62. Laville N, Balaguer P, Brion F, Hinfray N, Casellas C, Porcher J-M, Aït-Aïssa S. Modulation of aromatase activity and mRNA by various selected pesticides in the human choriocarcinoma JEG-3 cell line. Toxicology 2006; 228: 98-108
63. Tessier DM, Matsumura F. Increased ErbB-2 Tyrosine Kinase Activity, MAPK Phosphorylation, and cell proliferation in the prostate Cancer Cell Line LNCap following treatment by select pesticides. Toxicol Sci.2001; 60: 38-43
64. Bharathi SP, Raj HM, Jain S, Banerjee BD, Ahmed T, Arora VK. Role of pesticides in the induction of tumor angiogenesis. Anticancer Res. 2013;33:231-40
65. Careghini A, Mastorgio A, Saponaro S, Sezenna E. Bisphenol A, nonylphenols, benzophenones, and benzotriazoles in soils, groundwater, surface water, sediments, and food: a review. Environ Sci Pollut Res Int. 2015; 22: 5711-5741
66. Kim SH, Nam KH, Hwang KA, Choi KC. Influence of hexabromocyclododecane and 4-nonylphenol on the regulation of cell growth, apoptosis and migration in prostatic cancer cells.Toxicol In Vitro. 2016;32:240-7
67. Weidong G, Zhou M, Xiang Z, Han X, Li D. Combined Effects of Nonylphenol and Bisphenol A on the Human Prostate Epithelial Cell Line RWPE- Int J Environ Res Public Health. 2015; 12: 4141-4155
68. Li X, Xie W, Xie C, Huang C, Zhu J, Liang Z, Deng F, Zhu M, Zhu W, Wu R, Wu J, Geng S, Zhong C Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation. Phytother Res. 2014;28:1553-60
69. Itsiopoulos C, Hodge A, Kaimakamis M. Can the Mediterranean diet prevent prostate cancer? Mol Nutr Food Res. 2009; 53:227-39
70. Wigle, D. T., Turner, M. C., Gomes, J., Parent, M. E. Role of hormonal and other factors in human prostate cancer, J. Toxicol.Environ.HealthBCrit.Rev. 2008;11,242-259
71. Chen J, Song Y, Zhang L.J. Lycopene/tomato consumption and the risk of prostate cancer: a systematic review and meta-analysis of prospective studies. Nutr Sci Vitaminol. 2013; 59:213-23
72. Ambrosini G L, Fritschi L, de Klerk N.H, Mackerras D, Leavy, J. Dietary patterns identified using factor analysis and prostate cancer risk: A case control study in Western Australia, Ann. Epidemiol. 2008; 18:364-370
73. Jové M, Naudí A, Portero-Otin M, Cabré R, Rovira-Llopis S, Bañuls C, Rocha M, Hernández-Mijares A, Victor VM, Pamplona R. Plasma lipidomics discloses metabolic syndrome with a specific HDL phenotype. FASEB J. 2014;28:5163-71
74. Narayanan N. K, Narayanan B A, Reddy BS. A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro an disassociated with modulation of nuclearf actor-kappaB,and steroid ormone receptors,. Int.J.Oncol.2005,26,785-792
75. Carpentier YA, Portois, Malaisse W. n3 Fatty acids and the metabolic syndrome. Am J Clin Nutr. 2006; 83: S1499-1504S
76. Brasky T, Darke A, Song X, Tangen C, Goodman P, Thompson I, Meyskens J, Goodman G, Minasian LM, Parnes H.L, Klein E.A, Kristal A.R. Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial. J Natl Cancer Inst. 2013;105:1132-41
77. Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim J. Arachidonic acid metabolism in human prostate cancer. Int J Oncol. 2012;41:1495-503
78. Wigle, D. T., Turner, M. C., Gomes, J., Parent, M. E. Role of hormonal and other factors in human prostate cancer. J. Toxicol.Environ.HealthBCrit.Rev.2008;11,242-259
79. Schwartz, G.G., Hill, C.C., Oeler, T.A., Becich, M.J., Bahns on, R. R. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology. 1995;46, 365-369
80. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J .A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer, PLoS Med. 2007,4,e103
81. Ahn J, Park S, Zuniga B, Bera A, Song CS, Chatterjee B. Vitamin D in Prostate Cancer. Vitam Horm. 2016;100:321-55
82. Kristal A, Darke A, Morris S, Tangen C, Goodman P, Thompson I, Meyskens J, Goodman G, Minasian L, Parnes H, Scott M. Lippman, Klein E. Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk. JNCI J Natl Cancer Inst .2014; 106: djt456
83. WCRF-AICR, Food, Nutrition, Physical Activity, and the Prevention of Cancer: AGlobal Perspective, WCRF-AICR, WashingtonDC. 2007
84. Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res. 1998 ;58:442-7
85. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the Health Professionals Follow-up Study. International Journal of Cancer. 2007; 121:1571-78
86. Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjønneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, et al. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007;86:672-681
87. Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev. 2004;13:340-345
88. Quagliariello V, Iaffaioli RV, Falcone M, Ferrari G, Pataro G, Donsì F. Effect of pulsed electric fields-assisted extraction on anti-inflammatory and cytotoxic activity of brown rice bioactive compounds.Food Research International. 2016; 87:115-124
89. Kuno T, Nagano A, Mori Y, Kato H, Nagayasu Y, Naiki-Ito A, Suzuki S, Mori H, Takahashi S. Preventive Effects of Fermented Brown Rice and Rice Bran against Prostate Carcinogenesis in TRAP Rats. Nutrients. 2016; 8:421
90. Erolu C, Seçme M, Bac G, Dodurga Y. Assessment of the anticancer mechanism of ferulic acid via cell cycle and apoptotic pathways in human prostate cancer cell lines. Tumour Biol. 2015;36:9437-46